Association of leukemia target genes TET2, BCL2, and SLC23A2 in Vitamin C pathways

Jing Li, Wenqi Zhang, Weidong Liu, Jarrett Rong, Yuhan Chen, Weikuan Gu, Wei Zhang

Research output: Contribution to journalArticle

Abstract

Background: Vitamin C has been used in combination with several target genes in the treatment of leukemia. Tet methylcytosine dioxygenase (Tet2), B-cell lymphoma 2 (Bcl2), and solute carrier family 23 member 2 (Slc23a2) are the major target genes in the treatment of leukemia and are relevant to vitamin C. Materials and Methods: Using whole-genome expression profiles from mouse livers, the expression quantitative trait locus (eQTL), correlation matrix, and gene network graph were constructed with probes from each of these three genes and with their relative genes. The function of key genes was examined by their pathways and reported information. The results indicated that although direct correlations among their expression levels were not strong, alternative connecting pathways were discovered. By comparing the expression levels of one probe with known sequences from each of the three genes, we identified several key genes, induced myeloid leukemia cell differentiation protein (Mcl1), far upstream element-binding protein 1 (Fubp1), and tumor protein D52-like 2 (Tpd52l2), which play important roles in acute lymphocytic leukemia and acute myelocytic leukemia. In conclusion, Alternative pathways and key genes that connect Tet2, Bcl2, and Slc23a2 for their therapeutic applications with vitamin C were identified.

Original languageEnglish (US)
Pages (from-to)333-344
Number of pages12
JournalCancer Genomics and Proteomics
Volume16
Issue number5
DOIs
StatePublished - Jan 1 2019

Fingerprint

B-Cell Lymphoma
Ascorbic Acid
Leukemia
Genes
Dioxygenases
Myeloid Leukemia
Gene Regulatory Networks
Quantitative Trait Loci
Myeloid Cells
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Acute Myeloid Leukemia
Cell Differentiation
Carrier Proteins
Proteins
Liver
Genome
Tumors
Cells

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Association of leukemia target genes TET2, BCL2, and SLC23A2 in Vitamin C pathways. / Li, Jing; Zhang, Wenqi; Liu, Weidong; Rong, Jarrett; Chen, Yuhan; Gu, Weikuan; Zhang, Wei.

In: Cancer Genomics and Proteomics, Vol. 16, No. 5, 01.01.2019, p. 333-344.

Research output: Contribution to journalArticle

Li, Jing ; Zhang, Wenqi ; Liu, Weidong ; Rong, Jarrett ; Chen, Yuhan ; Gu, Weikuan ; Zhang, Wei. / Association of leukemia target genes TET2, BCL2, and SLC23A2 in Vitamin C pathways. In: Cancer Genomics and Proteomics. 2019 ; Vol. 16, No. 5. pp. 333-344.
@article{902bc6a4fecc4b2cbe6d2f98571d73e9,
title = "Association of leukemia target genes TET2, BCL2, and SLC23A2 in Vitamin C pathways",
abstract = "Background: Vitamin C has been used in combination with several target genes in the treatment of leukemia. Tet methylcytosine dioxygenase (Tet2), B-cell lymphoma 2 (Bcl2), and solute carrier family 23 member 2 (Slc23a2) are the major target genes in the treatment of leukemia and are relevant to vitamin C. Materials and Methods: Using whole-genome expression profiles from mouse livers, the expression quantitative trait locus (eQTL), correlation matrix, and gene network graph were constructed with probes from each of these three genes and with their relative genes. The function of key genes was examined by their pathways and reported information. The results indicated that although direct correlations among their expression levels were not strong, alternative connecting pathways were discovered. By comparing the expression levels of one probe with known sequences from each of the three genes, we identified several key genes, induced myeloid leukemia cell differentiation protein (Mcl1), far upstream element-binding protein 1 (Fubp1), and tumor protein D52-like 2 (Tpd52l2), which play important roles in acute lymphocytic leukemia and acute myelocytic leukemia. In conclusion, Alternative pathways and key genes that connect Tet2, Bcl2, and Slc23a2 for their therapeutic applications with vitamin C were identified.",
author = "Jing Li and Wenqi Zhang and Weidong Liu and Jarrett Rong and Yuhan Chen and Weikuan Gu and Wei Zhang",
year = "2019",
month = "1",
day = "1",
doi = "10.21873/cgp.20138",
language = "English (US)",
volume = "16",
pages = "333--344",
journal = "Cancer Genomics and Proteomics",
issn = "1109-6535",
publisher = "International Institute of Anticancer Research",
number = "5",

}

TY - JOUR

T1 - Association of leukemia target genes TET2, BCL2, and SLC23A2 in Vitamin C pathways

AU - Li, Jing

AU - Zhang, Wenqi

AU - Liu, Weidong

AU - Rong, Jarrett

AU - Chen, Yuhan

AU - Gu, Weikuan

AU - Zhang, Wei

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: Vitamin C has been used in combination with several target genes in the treatment of leukemia. Tet methylcytosine dioxygenase (Tet2), B-cell lymphoma 2 (Bcl2), and solute carrier family 23 member 2 (Slc23a2) are the major target genes in the treatment of leukemia and are relevant to vitamin C. Materials and Methods: Using whole-genome expression profiles from mouse livers, the expression quantitative trait locus (eQTL), correlation matrix, and gene network graph were constructed with probes from each of these three genes and with their relative genes. The function of key genes was examined by their pathways and reported information. The results indicated that although direct correlations among their expression levels were not strong, alternative connecting pathways were discovered. By comparing the expression levels of one probe with known sequences from each of the three genes, we identified several key genes, induced myeloid leukemia cell differentiation protein (Mcl1), far upstream element-binding protein 1 (Fubp1), and tumor protein D52-like 2 (Tpd52l2), which play important roles in acute lymphocytic leukemia and acute myelocytic leukemia. In conclusion, Alternative pathways and key genes that connect Tet2, Bcl2, and Slc23a2 for their therapeutic applications with vitamin C were identified.

AB - Background: Vitamin C has been used in combination with several target genes in the treatment of leukemia. Tet methylcytosine dioxygenase (Tet2), B-cell lymphoma 2 (Bcl2), and solute carrier family 23 member 2 (Slc23a2) are the major target genes in the treatment of leukemia and are relevant to vitamin C. Materials and Methods: Using whole-genome expression profiles from mouse livers, the expression quantitative trait locus (eQTL), correlation matrix, and gene network graph were constructed with probes from each of these three genes and with their relative genes. The function of key genes was examined by their pathways and reported information. The results indicated that although direct correlations among their expression levels were not strong, alternative connecting pathways were discovered. By comparing the expression levels of one probe with known sequences from each of the three genes, we identified several key genes, induced myeloid leukemia cell differentiation protein (Mcl1), far upstream element-binding protein 1 (Fubp1), and tumor protein D52-like 2 (Tpd52l2), which play important roles in acute lymphocytic leukemia and acute myelocytic leukemia. In conclusion, Alternative pathways and key genes that connect Tet2, Bcl2, and Slc23a2 for their therapeutic applications with vitamin C were identified.

UR - http://www.scopus.com/inward/record.url?scp=85071766779&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071766779&partnerID=8YFLogxK

U2 - 10.21873/cgp.20138

DO - 10.21873/cgp.20138

M3 - Article

VL - 16

SP - 333

EP - 344

JO - Cancer Genomics and Proteomics

JF - Cancer Genomics and Proteomics

SN - 1109-6535

IS - 5

ER -